A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial.

Simon Gampenrieder; A Risch; G Rinnerthaler; H Hackl; M. Steiner; Walter Pulverer; Andreas Weinhäusel; Suzana Ilic; Clemens Hufnagl; Cornelia Hauser-Kronberger; A Egle; R. Greil

A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial.

Simon Gampenrieder (Vortragende:r), A Risch, G Rinnerthaler, H Hackl, M. Steiner, Walter Pulverer, Andreas Weinhäusel, Suzana Ilic, Clemens Hufnagl, Cornelia Hauser-Kronberger, A Egle, R. Greil

Molecular Diagnostics

Publikation: Posterpräsentation ohne Beitrag in Tagungsband › Posterpräsentation ohne Eintrag in Tagungsband › Begutachtung

Originalsprache	Englisch
Publikationsstatus	Veröffentlicht - 2018
Veranstaltung	San Antonio Breast Cancer Symposium 2018 - Dauer: 4 Dez. 2018 → 8 Dez. 2018

Konferenz

Konferenz	San Antonio Breast Cancer Symposium 2018
Zeitraum	4/12/18 → 8/12/18

Research Field

Molecular Diagnostics

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Diese Publikation zitieren

Gampenrieder, S., Risch, A., Rinnerthaler, G., Hackl, H., Steiner, M., Pulverer, W., Weinhäusel, A., Ilic, S., Hufnagl, C., Hauser-Kronberger, C., Egle, A., & Greil, R. (2018). A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial.. Beitrag in San Antonio Breast Cancer Symposium 2018.

@conference{e6e5b0662bd94b1bb934c10b531e0913,

title = "A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial.",

author = "Simon Gampenrieder and A Risch and G Rinnerthaler and H Hackl and M. Steiner and Walter Pulverer and Andreas Weinh{\"a}usel and Suzana Ilic and Clemens Hufnagl and Cornelia Hauser-Kronberger and A Egle and R. Greil",

year = "2018",

language = "English",

note = "San Antonio Breast Cancer Symposium 2018 ; Conference date: 04-12-2018 Through 08-12-2018",

}

Gampenrieder, S, Risch, A, Rinnerthaler, G, Hackl, H, Steiner, M, Pulverer, W , Weinhäusel, A, Ilic, S, Hufnagl, C, Hauser-Kronberger, C, Egle, A & Greil, R 2018, 'A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial.', Beitrag in San Antonio Breast Cancer Symposium 2018, 4/12/18 - 8/12/18.

A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. / Gampenrieder, Simon (Vortragende:r); Risch, A; Rinnerthaler, G et al.
2018. Beitrag in San Antonio Breast Cancer Symposium 2018.

Publikation: Posterpräsentation ohne Beitrag in Tagungsband › Posterpräsentation ohne Eintrag in Tagungsband › Begutachtung

TY - CONF

T1 - A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial.

AU - Risch, A

AU - Rinnerthaler, G

AU - Hackl, H

AU - Steiner, M.

AU - Pulverer, Walter

AU - Weinhäusel, Andreas

AU - Ilic, Suzana

AU - Hufnagl, Clemens

AU - Hauser-Kronberger, Cornelia

AU - Egle, A

AU - Greil, R.

A2 - Gampenrieder, Simon

PY - 2018

Y1 - 2018

M3 - Poster presentation without proceedings

T2 - San Antonio Breast Cancer Symposium 2018

Y2 - 4 December 2018 through 8 December 2018

ER -